Company: VRCA
Filing Date: 2025-07-23
Form Type: 8-K
Source: 0001193125-25-162939
Chunk: 0

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-07-23
Form: 8-K
Item: Item 3.03
Chunk 0
---
Item 3.03 Material Modification to Rights of Security Holders.

(a)

On July 22, 2025, Verrica Pharmaceuticals Inc. (the “ Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of1-for-10(the “ Charter Amendment”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s Annual Meeting of Stockholders held on June 5, 2025.

Pursuant to the Charter Amendment, effective at 5:00 p. m. Eastern Time on July 24, 2025 (the “ Effective Time”), every 10 shares of the Company’s issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. As a result of the reverse stock split, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding at the Effective Time, which will result in a proportional decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise of such stock options and warrants, and a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company’s 2018 Equity Incentive Plan and 2024 Inducement Plan immediately prior to the Effective Time will be reduced proportionately.

No fractional shares will be issued as a result of the reverse stock split. Stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof. The reverse stock split will affect all stockholders proportionately and will not affect any stockholder’s percentage ownership of the Company’s common stock (except to the extent that the reverse stock split results in any stockholder owning only a fractional share).

The Company’s common stock will begin trading on The Nasdaq Global Market on a split-adjusted basis when the market opens on July 25, 2025. The new CUSIP number for the Company’s common stock following the reverse stock split will be 92511W207.

As of July 11, 2025, there were approximately 92.5 million shares of common stock outstanding. Immediately following the reverse stock split, there will be approximately 9.25 million shares of common stock outstanding (subject to adjustment due to